Ownership and insider activity for Q32 Bio Inc. (QTTB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation.
Price
| Price | $10.98 |
| Market Cap | $327M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.4M | $51.6M | $38.2M | $53.8M | $217.4M | $108.4M | $34.0M | $25.6M | $78.0M | $48.3M |
| Short-term Investments | 0 | $78.1M | $176.5M | $208.6M | 0 | $47.5M | $141.0M | 0 | 0 | 0 |
| Receivables | $113260 | 0 | $800000 | $400000 | $400000 | 0 | $1.1M | $755000 | $555000 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $12.0M | $131.6M | $221.7M | $266.6M | $219.6M | $191.9M | $182.1M | $28.7M | $81.9M | $55.0M |
| Property, Plant & Equipment | $2.0M | $3.2M | $35.6M | $42.7M | $42.9M | $17.9M | $21.6M | $8.1M | $7.1M | $6.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $14.2M | $137.5M | $259.1M | $310.6M | $263.7M | $211.7M | $229.5M | $47.1M | $92.3M | $61.8M |
| Accounts Payable | $893673 | $2.5M | $15.7M | $2.6M | $4.7M | $2.4M | $1.4M | $3.5M | $3.0M | $879000 |
| Short-term Debt | 0 | 0 | 0 | 0 | $2.5M | $246000 | $1.6M | $878000 | $3.1M | $6.9M |
| Total Current Liabilities | $6.4M | $8.9M | $22.5M | $12.4M | $22.7M | $17.2M | $23.6M | $14.1M | $16.5M | $11.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $43.2M | $9.6M | $3.5M |
| Total Liabilities | $6.7M | $39.2M | $62.7M | $52.1M | $67.7M | $42.1M | $51.5M | $230.0M | $86.7M | $19.8M |
| Retained Earnings | -$10.2M | -$40.2M | -$95.8M | -$199.7M | -$328.4M | -$424.1M | -$429.1M | -$187.1M | -$234.8M | -$205.0M |
| Total Equity | $7.5M | $98.3M | $196.4M | $258.5M | $196.0M | $169.7M | $178.0M | -$182.9M | $5.7M | $42.0M |
| Total Debt | 0 | 0 | 0 | 0 | $15.4M | $23.9M | $29.9M | $50.8M | $18.9M | $15.3M |
| Net Debt | -$11.4M | -$129.7M | -$214.7M | -$262.4M | -$202.0M | -$131.9M | -$145.1M | $25.2M | -$59.1M | -$33.0M |
| Working Capital | $5.6M | $122.7M | $199.2M | $254.2M | $196.9M | $174.7M | $158.5M | $14.6M | $65.4M | $43.7M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 20.30 |
Profitability
| Return on Equity | 76.88% |
| Return on Invested Capital | 19.30% |
| Return on Assets | 29.16% |
| Gross Margin | 99.84% |
| Operating Margin | 39.94% |
| Net Margin | 62.87% |
Related companies: ANTX · BOLD · GBIO · INTS · ITRM · NXTC · PSTV
Explore sector: Healthcare · Biotechnology
More sections of QTTB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks